CTOR Valuation

Citius Oncology Inc

Add to Watchlist

Advanced Chart

2.170

+0.05(2.358%)1D

Overview
Forecast
Valuation
Earnings

CTOR Relative Valuation

CTOR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTOR is overvalued; if below, it's undervalued.

Historical Valuation

Citius Oncology Inc (CTOR) is now in the Fair zone, suggesting that its current forward PS ratio of 3.20 is considered Fairly compared with the five-year average of 5.09. The fair price of Citius Oncology Inc (CTOR) is between 0.40 to 2.78 according to relative valuation methord.

Relative Value

Fair Zone

0.40-2.78

Current Price：2.17

Fair

108.50

Trailing

Forward

0.00

EV/EBITDA

Citius Oncology Inc. (CTOR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

14.48

EV/EBIT

Citius Oncology Inc. (CTOR) has a current EV/EBIT of 14.48. The 5-year average EV/EBIT is -26.74. The thresholds are as follows: Strongly Undervalued below -226.63, Undervalued between -226.63 and -126.69, Fairly Valued between 73.20 and -126.69, Overvalued between 73.20 and 173.14, and Strongly Overvalued above 173.14. The current Forward EV/EBIT of 14.48 falls within the Historic Trend Line -Fairly Valued range.

3.20

Citius Oncology Inc. (CTOR) has a current PS of 3.20. The 5-year average PS is 1.17. The thresholds are as follows: Strongly Undervalued below -2.71, Undervalued between -2.71 and -0.77, Fairly Valued between 3.12 and -0.77, Overvalued between 3.12 and 5.06, and Strongly Overvalued above 5.06. The current Forward PS of 3.20 falls within the Overvalued range.

0.00

P/OCF

Citius Oncology Inc. (CTOR) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Citius Oncology Inc. (CTOR) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.80. The thresholds are as follows: Strongly Undervalued below -10.04, Undervalued between -10.04 and -5.92, Fairly Valued between 2.32 and -5.92, Overvalued between 2.32 and 6.44, and Strongly Overvalued above 6.44. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Citius Oncology Inc (CTOR) has a current Price-to-Book (P/B) ratio of 4.79. Compared to its 3-year average P/B ratio of 16.19 , the current P/B ratio is approximately -70.40% higher. Relative to its 5-year average P/B ratio of 16.19, the current P/B ratio is about -70.40% higher. Citius Oncology Inc (CTOR) has a Forward Free Cash Flow (FCF) yield of approximately 0.07%. Compared to its 3-year average FCF yield of 0.05%, the current FCF yield is approximately 35.31% lower. Relative to its 5-year average FCF yield of 0.05% , the current FCF yield is about 35.31% lower.

4.79

P/B

Median3y

16.19

Median5y

16.19

0.07

FCF Yield

Median3y

0.05

Median5y

0.05

Competitors Valuation Multiple

The average P/S ratio for CTOR's competitors is 2.11, providing a benchmark for relative valuation. Citius Oncology Inc Corp (CTOR) exhibits a P/S ratio of 3.20, which is 51.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

China SXT Pharmaceuticals Inc

Performance Decomposition

Market capitalization of CTOR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CTOR in the past 1 year is driven by Unknown.